期刊
TRANSPLANTATION AND CELLULAR THERAPY
卷 28, 期 1, 页码 -出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jtct.2021.10.007
关键词
CAR T-cell therapy; Cellular therapy; Cell-free DNA; Tumor marker
资金
- Joan and Irwin Jacobs Fund
- National Cancer Institute [P30 CA023100]
- Laboratory Corporation of America (Labcorp)
- NIH [T32-4T32EB005970]
- Labcorp
This study aims to demonstrate the feasibility of using cfDNA to predict CAR-T cell therapy response in patients with refractory B-cell lymphomas. The results provide a proof-of-concept for the use of multiple liquid biopsy technologies to monitor therapeutic response in these patients.
Methods that enable monitoring of therapeutic efficacy of autologous chimeric antigen receptor (CAR) T-cell therapy will be clinically useful. The aim of this study is to demonstrate the feasibility of blood-derived cell-free DNA (cfDNA) to predict CAR T-cell therapy response in patients with refractory B-cell lymphomas. Whole blood was collected before and throughout CAR T-cell therapy until day 154. Low-coverage (& raquo;0.4 ) pound, genome-wide cfDNA sequencing, similar to that established for noninvasive prenatal testing, was performed. The genomic instability number (GIN) was used to quantify plasma copy number alteration level. Twelve patients were enrolled. Seven (58%) patients achieved a complete response (CR); 2 (25%), a partial response. Median progression-free survival was 99 days; median overall survival was not reached (median follow-up, 247 days). Altogether, 127 blood samples were analyzed (median, 10 samples/patient [range 8-13]). All 5 patients who remained in CR at the time of last measurement had GIN < 170 (threshold). Two patients who attained CR, but later relapsed, and all but one patient who had best response other than CR had last GIN measurement of > 170. In 5 of 6 patients with relapsed or progressive disease, increasing GIN was observed before the diagnosis by imaging. The abundance of CAR T-cell construct (absolute number of construct copies relative to the number of human genome equivalents) also showed a trend to correlate with outcome (day 10, P = .052). These data describe a proof-of-concept for the use of multiple liquid biopsy technologies to monitor therapeutic response in B-cell lymphoma patients receiving CAR T-cell therapy. (c) 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据